MK-4827 (Niraparib): Selective PARP-1/-2 Inhibitor for BRCA-Mutant Cancer Research

Executive Summary: MK-4827 (Niraparib) is a highly selective, orally bioavailable small molecule inhibitor of PARP-1 and PARP-2 with IC₅₀ values of 3.8 nM and 2.1 nM, respectively, under standard in vitro enzymatic conditions (pH 7.4, 25°C) (APExBIO). It blocks poly(ADP-ribosyl)ation, impairs DNA repair, and induces synthetic lethality in BRCA-1/2-mutated cancer cells while sparing normal cells at micromolar concentrations (3xflag.com). In vivo, MK-4827 shows robust antitumor activity in BRCA-mutant xenograft models and potentiates radiotherapy with minimal toxicity. Its solubility profile (≥32 mg/mL in DMSO, ≥50.9 mg/mL in ethanol, insoluble in water) enables flexible formulation for research. MK-4827 is a benchmark tool for dissecting DNA damage response and overcoming PARP inhibitor resistance in translational cancer research (3xflag.com).

Biological Rationale

Poly(ADP-ribose) polymerases (PARPs) are nuclear enzymes that catalyze the transfer of ADP-ribose units from β-NAD⁺ onto target proteins, a process known as poly(ADP-ribosyl)ation. PARP-1 and PARP-2 are central to the DNA damage response, facilitating single-strand DNA break repair via base excision repair (BER). Loss of function in homologous recombination repair—such as BRCA-1 or BRCA-2 mutations—renders cancer cells highly dependent on PARP-mediated repair. Inhibiting PARP in these contexts leads to synthetic lethality, selectively killing deficient tumor cells while sparing normal tissue. MK-4827 (Niraparib), by targeting PARP-1 and PARP-2, enables researchers to model and exploit these vulnerabilities in BRCA-mutant and DNA repair-deficient cancers (olaparib.net).

Mechanism of Action of MK-4827 (Niraparib), a potent and selective PARP-1/-2 inhibitor

MK-4827 (Niraparib) is a competitive inhibitor of the β-NAD⁺ binding site on PARP-1 and PARP-2, effectively blocking PARP enzymatic activity. The compound exhibits high selectivity, with IC₅₀ values of 3.8 nM for PARP-1 and 2.1 nM for PARP-2, as measured in standard biochemical assays at 25°C and neutral pH. Inhibition of PARP prevents poly(ADP-ribosyl)ation, leading to accumulation of DNA single-strand breaks and collapse of replication forks. In BRCA-1/2-mutant cells, which lack efficient homologous recombination repair, this results in cell death via synthetic lethality. MK-4827 thereby impedes tumor cell proliferation, especially in DNA repair-deficient models. The specificity of MK-4827 for PARP-1/-2 limits off-target effects, making it ideal for mechanistic and translational research (APExBIO).

Evidence & Benchmarks

• MK-4827 (Niraparib) inhibits PARP-1 and PARP-2 with IC₅₀ values of 3.8 nM and 2.1 nM, respectively, using in vitro activity assays (APExBIO, product page).
• In BRCA-1 and BRCA-2 mutant cell lines, MK-4827 demonstrates antiproliferative CC₅₀ values between 10–100 nM, while normal epithelial cells display resistance at concentrations ≥1 μM (APExBIO, product page).
• In vivo studies show significant tumor growth inhibition in BRCA-1 mutant MDA-MB-436 breast cancer xenografts and in diverse lung cancer models with variable p53 status (APExBIO, product page).
• MK-4827 enhances the therapeutic effect of radiotherapy in preclinical models, with good tolerability and minimal toxicity (Mei et al., Mol Cancer Ther 2025).
• Maintenance therapy with MK-4827 following platinum (cisplatin) chemotherapy improves survival in epithelial ovarian cancer (EOC) models, particularly when combined with all-trans retinoic acid (ATRA) (Mei et al., Mol Cancer Ther 2025).
• PARP inhibitor resistance in EOC is associated with elevated PARP1, ALDH1A1, and NAD⁺ levels, which can be mitigated by ATRA co-treatment (Mei et al., Mol Cancer Ther 2025).

Compared to the review at 3xflag.com, which explores combination therapies and resistance mechanisms, this article provides a granular, citation-dense summary of MK-4827's pharmacology, benchmarks, and actionable workflow parameters for experimentalists. For further strategic insights and translational context, see pci32765.com, which focuses on strategic frameworks for DNA repair-targeted research, extending the practical application guidance found here.

Applications, Limits & Misconceptions

MK-4827 (Niraparib) is widely used for:

• Assessment of DNA damage response and repair pathway inhibition in cancer cells.
• Modeling synthetic lethality in BRCA-1/2 mutant and homologous recombination-deficient (HRD) tumors.
• Dissecting mechanisms of PARP inhibitor resistance, including adaptive and acquired resistance following platinum chemotherapy (Mol Cancer Ther 2025).
• Evaluating radiosensitization and chemosensitization strategies in preclinical models.
• Benchmarking small molecule PARP inhibition in translational and drug discovery workflows (olaparib.net).

Common Pitfalls or Misconceptions

• MK-4827 is not effective against all mechanisms of chemoresistance. Resistance due to restoration of homologous recombination or replication fork protection can limit efficacy (Mol Cancer Ther 2025).
• Not all BRCA wild-type tumors are sensitive. Activity is most pronounced in BRCA-mutant or HRD models; efficacy in HR-proficient cancers is variable (Mol Cancer Ther 2025).
• MK-4827 is insoluble in water. Use DMSO or ethanol for stock solutions; improper solvents can result in precipitation and loss of potency (APExBIO).
• Long-term storage of solutions is discouraged. MK-4827 should be stored at -20°C as a solid, and solutions should be prepared freshly (APExBIO).
• In vitro potency does not guarantee in vivo efficacy. Tumor microenvironment, drug metabolism, and resistance mechanisms can affect outcomes (3xflag.com).

Workflow Integration & Parameters

MK-4827 (Niraparib) can be seamlessly integrated into DNA repair pathway studies, cancer cell proliferation assays, and xenograft models. For in vitro applications, prepare stock solutions at 10–50 mM in DMSO or ethanol (gently warmed if needed). Final working concentrations in cell-based assays typically range from 10 nM to 1 μM, depending on cell line sensitivity. For in vivo studies, dosing regimens should be based on published benchmarks (e.g., 50 mg/kg oral gavage, daily, in mice), with careful monitoring of tolerability and toxicity. Avoid repeated freeze-thaw cycles and long-term storage of prepared solutions. The A3617 kit from APExBIO provides quality-assured MK-4827 for reproducible results (APExBIO).

For advanced translational workflows and strategic deployment, see the discussion at pci32765.com, which complements this guide by highlighting resistance management and workflow integration for DNA repair-targeted drug development.

Conclusion & Outlook

MK-4827 (Niraparib) is a gold-standard selective PARP-1/-2 inhibitor for BRCA-mutant cancer research, enabling robust mechanistic studies and translational advances in DNA repair inhibition. Its nanomolar potency, high selectivity, and favorable in vivo profile have positioned it as a foundational tool for preclinical and translational oncologic discovery. As resistance mechanisms emerge, integration with combination strategies (e.g., retinoic acid or radiotherapy) and evolving workflows will further refine its application space. For detailed product specifications and ordering, refer to the APExBIO MK-4827 (Niraparib), a potent and selective PARP-1/-2 inhibitor product page.